This page gives the users the articles related to half-life of peptides and their link on Pubmed.
| Title | PMID |
|---|---|
| A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity. | 26400022 |
| A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis. | 26337231 |
| In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue. | 26325323 |
| Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. | 26308095 |
| Degradation and Stabilization of Peptide Hormones in Human Blood Specimens. | 26222180 |
| The anorexic hormone Peptide YY3-36 is rapidly metabolized to inactive Peptide YY3-34 in vivo. | 26197931 |
| Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology. | 25900863 |
| A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer. | 25894376 |
| A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions. | 25771000 |
| Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. | 25625650 |
| Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity. | 25594223 |
| Myristic acid conjugation of [D-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetic profile and efficacy. | 25453979 |
| Assessment of Pharmacokinetics and Toxicology of Sadat-Habdan Mesenchymal Stimulating Peptide (SHMSP) in Rats and Goats. | 25324697 |
| Long-acting GLP-1 analogue in V-shaped conformation by terminal polylysine modifications. | 25243635 |
| Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. | 25039358 |
| A potent anti-thrombosis peptide (vasotab TY) from horsefly salivary glands. | 25025626 |
| Biological properties of adrenomedullin conjugated with polyethylene glycol. | 24874704 |
| Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. | 24588343 |
| Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin. | 24462899 |
| Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo. | 24378440 |
| Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. | 24361089 |
| Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA). | 24139844 |
| Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. | 24133142 |
| Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents. | 23836030 |
| First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. | 23813302 |
| Cytotoxicity and vitreous stability of chemically modified connexin43 mimetic peptides for the treatment of optic neuropathy. | 23696181 |
| Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. | 23318685 |
| The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. | 23318502 |
| In vitro and in vivo evaluation of a water-in-oil microemulsion system for enhanced peptide intestinal delivery. | 23196806 |
| Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. | 23099431 |
| Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. | 22934681 |
| Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation. | 22770564 |
| PEGylation of an osteoclast inhibitory peptide: suitable candidate for the treatment of osteoporosis. | 22698865 |
| The analysis of exogenous ghrelin plasma activity and tissue distribution. | 22592200 |
| A new strategy for metabolic stabilization of motilin using the C-terminal part of ghrelin. | 22286034 |
| Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats. | 22263969 |
| Microbial degradation of physiologically active peptides by strain B-9. | 22186872 |
| Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. | 21986100 |
| An LC-MS/MS assay to determine plasma pharmacokinetics of cyclic thymic hexapeptide (cTP6) in rhesus monkeys. | 21903490 |
| A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo. | 21664938 |
| Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. | 21459096 |
| Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo. | 21334413 |
| Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. | 21329733 |
| Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. | 21244372 |
| Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy. | 21210710 |
| Bactericidal oncocin derivatives with superior serum stabilities. | 21185160 |
| Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes. | 21114599 |
| Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. | 21036718 |
| Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. | 20844765 |
| Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. | 20687610 |
| Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. | 20631047 |
| Synthesis and characterization of ester-based prodrugs of glucagon-like peptide 1. | 20593470 |
| Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa. | 20587645 |
| Easy strategy to protect antimicrobial peptides from fast degradation in serum. | 20585128 |
| Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists. | 20560643 |
| Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. | 20503261 |
| Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. | 20418955 |
| Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. | 20382695 |
| A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection. | 20221650 |
| Biodistribution and pharmacokinetics of PEG-10kDa-cholecystokinin-10 in rats after different routes of administration. | 20158487 |
| A sandwich ELISA for assessment of pharmacokinetics of HSA-(BNP)2 fusion protein in mouse plasma. | 19836183 |
| Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. | 19805567 |
| Differential elicitation of an aspartic protease inhibitor: regulation of endogenous protease and initial events in germination in seeds of Vigna radiata. | 19770015 |
| Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. | 19767127 |
| The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. | 19762245 |
| Design of proteolytically stable RI-anchoring disruptor peptidomimetics for in vivo studies of anchored type I protein kinase A-mediated signalling. | 19715558 |
| Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. | 19602537 |
| TAT peptide and its conjugates: proteolytic stability. | 19601640 |
| Effect of PEGylation of N-WASP181-200 on the inhibitory potency for renal aminoglycoside accumulation. | 19572636 |
| Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. | 19552923 |
| Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies. | 19533722 |
| Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation. | 19531053 |
| A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation. | 19458086 |
| Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. | 19422857 |
| Studies of poly(ethylene glycol) modification of HM-3 polypeptides. | 19413309 |
| Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation. | 19403044 |
| Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. | 19344673 |
| Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects. | 19224155 |
| Identification and characterization of a peptide with affinity to head and neck cancer. | 19223422 |
| N-terminal pro-brain natriuretic peptide and atrial fibrillation. | 19165353 |
| Rapid profiling of peptide stability in proteolytic environments. | 19159331 |
| NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. | 19157421 |
| The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo. | 19115392 |
| Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. | 19053766 |
| A combined in vitro and in vivo study on the interactions between somatostatin and lipid-based liquid crystalline drug carriers and bilayers. | 19041716 |
| Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization. | 19023544 |
| Degradation of salmon calcitonin in rat kidney and liver homogenates. | 18972837 |
| Carbofuran poisoning detected by mass spectrometry of butyrylcholinesterase adduct in human serum. | 18937214 |
| Estrogen elevates the peak overnight production rate of acylated ghrelin. | 18697865 |
| 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. | 18632826 |
| In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. | 18602197 |
| N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery. | 18586440 |
| Evaluation of postmortem measurement of NT-proBNP as a marker for cardiac function. | 18553094 |
| Synthetic collagen heterotrimers: structural mimics of wild-type and mutant collagen type I. | 18481852 |
| N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. | 18424366 |
| Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. | 18413862 |
| Novel stable PACAP analogs with potent activity towards the PAC1 receptor. | 18353507 |
| Antimicrobial peptides with stability toward tryptic degradation. | 18307313 |
| Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. | 18249125 |
| Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. | 18085721 |
| Pharmacokinetics and pharmacology of hirulog-like peptide. | 18049308 |
| Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. | 17994612 |
| One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique. | 17986790 |
| Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. | 17904340 |
| Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. | 17766836 |
| Influence of chelate conjugation on a newly identified tumor-targeting peptide. | 17704241 |
| Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. | 17684103 |
| NC100668, a new tracer tested for imaging of venous thromboembolism: pharmacokinetics and metabolism in humans. | 17682073 |
| Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. | 17640899 |
| Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. | 17583927 |
| Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. | 17537541 |
| In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. | 17532097 |
| Caco-2 cell permeability and stability of two d-glucopyranuronamide conjugates of thyrotropin-releasing hormone. | 17498958 |
| ANP is cleared much faster than BNP in patients with congestive heart failure. | 17479256 |
| Metabolism of cydiastatin 4 and analogues by enzymes associated with the midgut and haemolymph of Manduca sexta larvae. | 17408666 |
| Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. | 17374660 |
| Biological activity of AC3174, a peptide analog of exendin-4. | 17292977 |
| N-terminal pro-atrial natriuretic peptide and exercise prescription in patients with myocardial infarction. | 17292492 |
| Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. | 17283237 |
| Stability of synthetic exendin-4 in human plasma in vitro. | 17266646 |
| Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. | 17258819 |
| Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. | 17204551 |
| Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV. | 17107718 |
| Effects of peripheral administration of PYY3-36 on feed intake and plasma acyl-ghrelin levels in pigs. | 17065394 |
| cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. | 16990557 |
| Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. | 16982323 |
| Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. | 16892368 |
| Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. | 16828890 |
| PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. | 16586064 |
| Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. | 16476851 |
| Molecular basis for phosphorylation-dependent, PEST-mediated protein turnover. | 16472750 |
| Glioma cell integrin expression and their interactions with integrin antagonists: Research Article. | 16467916 |
| Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. | 16302271 |
| Hemostatic effects of phospholipid vesicles carrying fibrinogen gamma chain dodecapeptide in vitro and in vivo. | 16287259 |
| Stability and degradation profiles of Spantide II in aqueous solutions. | 16266798 |
| Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. | 16197609 |
| Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. | 16099941 |
| A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. | 16023182 |
| Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. | 15882144 |
| Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. | 15828822 |
| Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. | 15817669 |
| Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. | 15769092 |
| Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin. | 15740458 |
| Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. | 15656696 |
| AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. | 15587934 |
| The direct thrombin inhibitor melagatran/ximelagatran. | 15487959 |
| Half-life of leu-enkephalin in the serum of infants of the first year of life on different types of feeding: relationship with temperament. | 15452596 |
| Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. | 15369394 |
| Systemic catabolism of Alzheimer's Abeta40 and Abeta42. | 15322125 |
| Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. | 15246869 |
| N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. | 15012592 |
| Using spectrophotometry to determine in vitro turnover rates of peptides in plasma. | 14980787 |
| N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression. | 14759771 |
| Structure-based design of an indolicidin peptide analogue with increased protease stability. | 14640680 |
| PEGylation of growth hormone-releasing hormone (GRF) analogues. | 14499707 |
| In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues. | 12954066 |
| Haemodynamic action of B-type natriuretic peptide substantially outlasts its plasma half-life in conscious dogs. | 12859428 |
| Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. | 12852770 |
| Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. | 12699744 |
| Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. | 12578830 |
| Utilization of a radioimmunoassay to detect the generation of Arg-Pro-Pro-Gly-Phe, a stable endproduct of bradykinin metabolism (from cultured rat aortic smooth muscle cells exposed to bradykinin). | 12489813 |
| In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. | 12444298 |
| Albumin affinity tags increase peptide half-life in vivo. | 12270169 |
| A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. | 12220890 |
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. | 12145241 |
| Albumin binding as a general strategy for improving the pharmacokinetics of proteins. | 12119302 |
| Clinical pharmacokinetics of depot leuprorelin. | 12083977 |
| Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. | 12047915 |
| The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. | 12039708 |
| Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. | 11976797 |
| In vivo pharmacokinetics of calreticulin S-domain, an inhibitor of the classical complement pathway. | 11962721 |
| Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate. | 11778971 |
| The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. | 11553691 |
| Binding protein-3-selective insulin-like growth factor I variants: engineering, biodistributions, and clearance. | 11145579 |
| A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. | 11099487 |
| Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. | 11054637 |
| Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. | 10973845 |
| Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. | 10871321 |
| Designing stable blood-brain barrier-permeable prosaptide peptides for treatment of central nervous system neurodegeneration. | 10773009 |
| Biodistribution of liposomal 131I-VIP in rat using gamma camera. | 10708307 |
| Human thyrotropin-releasing hormone-associated peptide 3 (hTAP-3) in serum. | 10670753 |
| Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. | 10647619 |
| Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. | 10611139 |
| Transport of circulating IGF-I and LR3IGF-I from blood to extracellular wound fluid sites in rats. | 10607940 |
| Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration. | 10606160 |
| Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. | 10541299 |
| The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. | 10573295 |
| Bioconjugation of laminin-related peptide YIGSR with polyvinyl pyrrolidone increases its antimetastatic effect due to a longer plasma half-life. | 10544005 |
| Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. | 10495424 |
| Design, synthesis and characterization of antimicrobial pseudopeptides corresponding to membrane-active peptide. | 10461747 |
| PGFM response to exogenous oxytocin and determination of the half-life of oxytocin in nonpregnant mares. | 10454085 |
| The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. | 10377427 |
| Thioamides: synthesis, stability, and immunological activities of thioanalogues of Imreg. Preparation of new thioacylating agents using fluorobenzimidazolone derivatives. | 10354413 |
| Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematol... | 9932163 |
| gamma-secretase cleavage is distinct from endoplasmic reticulum degradation of the transmembrane domain of the amyloid precursor protein. | 9822665 |
| Pharmacokinetics of the bicyclic peptide tachykinin NK2 receptor antagonist MEN 11420 (nepadutant) in rats. | 9806949 |
| Converting enzyme determines plasma clearance of angiotensin-(1-7). | 9740616 |
| Disposition of 14C-eptifibatide after intravenous administration to healthy men. | 9589822 |
| Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. | 9421401 |
| Dynorphin A (1-8) analog, E-2078, is stable in human and rhesus monkey blood. | 9067297 |
| No. 302, a newly synthesized [pGlu4,Cyt6]AVP(4-9) analogue, prevents the disruption of avoidance behavior. | 9062685 |
| Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. | 9040091 |
| Processing of [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P in xenograft bearing Nu/Nu mice. | 9357069 |
| High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor. | 8910426 |
| Pharmacokinetics and toxicokinetics of an orally active tripeptide, IRI-695, in animals. | 8991489 |
| Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma. | 8839678 |
| Haemodynamic responses to rat adrenomedullin in anaesthetized spontaneously hypertensive rats. | 8542672 |
| Degradation of IGF-I in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein. | 7561632 |
| Radioimmunoassay for hexarelin, a peptidic growth hormone secretagogue, and its pharmacokinetic studies. | 8545255 |
| In vitro stability of some reduced peptide bond pseudopeptide analogues of dynorphin A. | 8545241 |
| Nasal mucosal metabolism and absorption of pentapeptide enkephalin analogs having varying N-terminal amino acids. | 7714746 |
| Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. | 7994807 |
| The effect of cyclodextrins on the stability of peptides in nasal enzymic systems. | 7899230 |
| Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. | 7962302 |
| Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. | 7529108 |
| In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera. | 9234336 |
| Heterogeneity in hepatic transport of somatostatin analog octapeptides. | 8020889 |
| Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-performance liquid chromatography. | 7522585 |
| Prevention of diabetes by thymic hormone in alloxan-treated rats. | 8082705 |
| N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. | 8181115 |
| Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. | 8076909 |
| The role of the kidney in the clearance of calcitonin gene related peptide (CGRP). | 8147781 |
| Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. | 8289671 |
| Synthetic human adrenomedullin and adrenomedullin 15-52 have potent short-lived vasodilator activity in the hindlimb vascular bed of the cat. | 8035644 |
| Pharmacokinetics and organ distribution of the sorbin C-terminal peptides. | 7991443 |
| Growth hormone-releasing activity of hexarelin in humans. A dose-response study. | 7957536 |
| Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. | 7911441 |
| Distribution and metabolism patterns of plasma 7S- and beta-NGF in the adult male rat. | 7787827 |
| Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. | 8257427 |
| Biphasic effects of suramin on 125I-epidermal growth factor binding to human meningiomas. | 8194082 |
| Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. | 8222093 |
| Atrial natriuretic factor and transgenic mice. | 8406670 |
| Mass spectrometry and characterization of Aedes aegypti trypsin modulating oostatic factor (TMOF) and its analogs. | 8353526 |
| Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. | 8353280 |
| The intrarenal site of calcitonin gene-related peptide degradation in the isolated perfused rat kidney. | 8403527 |
| Functional peptide-polyurethane conjugates with extended circulatory half-lives. | 8218482 |
| On the effects of human galanin in man. | 7689499 |
| Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells. | 8395230 |
| Effect of low dose infusions of ile-atrial natriuretic peptide in healthy elderly males: evidence for a postreceptor defect. | 8388403 |
| Desensitisation of the cardiac response to somatostatin in isolated toad atria but not in whole toads. | 8100840 |
| Optimization of cell culture conditions for the evaluation of the biological activities of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro, a natural hemoregulatory factor. | 8217216 |
| Low levels of somatomedin C in patients with the fibromyalgia syndrome. A possible link between sleep and muscle pain. | 1418002 |
| A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. | 1319455 |
| Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. | 1551497 |
| Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists. | 1329046 |
| The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. | 1730807 |
| Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. | 1490668 |
| Kinetics of atrial natriuretic peptide in young and elderly subjects. | 1387608 |
| Metabolic half-life of somatostatin and peptidase activities are altered in Alzheimer's disease. | 1346149 |
| Leucine aminopeptidase-like activity in Aplysia hemolymph rapidly degrades biologically active alpha-bag cell peptide fragments. | 1939259 |
| The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours. | 1911217 |
| Hypothalamic degradation of galanin(1-29) and galanin(1-16): identification and characterization of the peptidolytic products. | 1723638 |
| Effects of brain natriuretic peptide-45, a circulating form of rat brain natriuretic peptide, in spontaneously hypertensive rats. | 1664804 |
| Development of enzyme-linked immunosorbent assay for free human pro-colipase activation peptide (APGPR). | 1777964 |
| Oral sodium regulates extrahepatic metabolism of vasoactive intestinal peptide. | 1649728 |
| Influence of age and dose on the end-organ responses to atrial natriuretic peptide in humans. | 1651738 |
| Gonadotropin-releasing hormone (GnRH) analogs: relationship between their structure, proteolytic inactivation and pharmacokinetics in rats. | 1882091 |
| Accelerated in vitro degradation of CCK-58 in blood and plasma of patients with acute pancreatitis. | 1889124 |
| Plasma clearance and tissue binding of rANP[99-126] and iso-rANP[1-45] in the rat. | 1646465 |
| Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Replacement of asparagine residues by serine stabilizes. | 1904406 |
| Effects of atrial natriuretic peptide (99-126) in chronic renal disease in man. | 1831249 |
| In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma. | 1826667 |
| Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin. | 1824807 |
| Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS). | 1763193 |
| Glucagon-(19-29), a Ca2+ pump inhibitory peptide, is processed from glucagon in the rat liver plasma membrane by a thiol endopeptidase. | 2147684 |
| Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction. | 2147696 |
| In vivo metabolism of brain natriuretic peptide in the rat involves endopeptidase 24.11 and angiotensin converting enzyme. | 2175178 |
| Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat. | 1697165 |
| Peptide histidine valine: its haemodynamic actions and pharmacokinetics in man differ from those of vasoactive intestinal peptide and peptide histidine methionine. | 2162275 |
| Brain natriuretic peptide administered to man: actions and metabolism. | 2156886 |
| Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance. | 2182027 |
| Extended presence of antide (Nal-Lys GnRH antagonist) in circulation: prolonged duration of gonadotropin inhibition may derive from antide binding to serum proteins. | 2298867 |
| Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. | 2687064 |
| Transdermal peptide delivery. | 2533571 |
| Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis. | 2498387 |
| GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. | 2714145 |
| An in vitro system for study of effects of angiotensin I on cultured endothelial cells. | 2556215 |
| Simulation of the activation of fat body glycogen phosphorylase and trehalose synthesis by peptide hormones in the American cockroach. | 2624887 |
| Rectal absorption enhancement of des-enkephalin-gamma-endorphin (DE gamma E) by medium-chain glycerides and EDTA in conscious rats. | 2524034 |
| Pharmacokinetics of vasopressin and atrial natriuretic peptide in anesthetized rabbits. | 2521208 |
| Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. | 3147901 |
| Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. | 2970910 |
| Pharmacokinetics and organ-specific metabolism of calcitonin gene-related peptide in sheep. | 3261772 |
| Serum half-life and biological activity of mutants of human insulin-like growth factor I which do not bind to serum binding proteins. | 2454805 |
| Plasma half-lives of native and modified insulin-like growth factor-I in lambs. | 3379352 |
| Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. | 3343338 |
| A preliminary study of the pharmacodynamics and pharmacokinetics of a novel enkephalin analogue [Tyr-D.Arg-Gly-Phe (4NO2).Pro.NH2 (BW443C)] in healthy volunteers. | 3360050 |
| Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. | 3348603 |
| Studies of the in vitro human plasma degradation of methionine-enkephalin. | 3215483 |
| NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. | 2966345 |
| Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1-29)-amide. | 2896343 |
| Cardiac vagal action and plasma levels of neuropeptide Y following intravenous injection in the dog. | 3601235 |
| Pharmacokinetics of synthetic atrial natriuretic peptides in normal men. | 2953516 |
| Effects of insulin-like growth factor I (IGF-I) on growth hormone-releasing factor (GRF) and thyrotropin-releasing hormone (TRH) stimulation of growth hormone (GH) secretion in the domestic fowl (Gallus domesticus). | 3108068 |
| Kinetics of four 11C-labelled enkephalin peptides in the brain, pituitary and plasma of rhesus monkeys. | 3492729 |
| Plasma half-life of DDAVP in uraemic patients. | 3799211 |
| Direct radioimmunoassay for human atrial natriuretic peptide (hANP) and its clinical evaluation. | 2945560 |
| Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters. | 3768731 |
| Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. | 2939312 |
| Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. | 2940625 |
| Disappearance of atrial natriuretic factor from circulation in the rat. | 2942845 |
| In vivo interaction of synthetic acylated apopeptides with high density lipoproteins in rat. | 3080478 |
| Circulating somatostatin concentrations in healthy and cirrhotic subjects. | 2868381 |
| Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. | 2866222 |
| Synthesis and biological activity of pentapeptide analogues of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline. | 2991517 |
| Effects and pharmacokinetic properties of the rat/human corticotropin-releasing factor in rhesus monkeys. | 2988919 |
| Radioimmunoassay for human growth hormone-releasing factor (hGRF 1-40): comparison of plasma immunoreactive GRF after intravenous and subcutaneous administration to rats. | 3924685 |
| Des-Tyr1-gamma-endorphin (DT gamma E) and des-enkephalin-gamma-endorphin (DE gamma E): plasma profile and brain uptake after systemic administration in the rat. | 4070016 |
| Enkephalin pseudopeptides: resistance to in vitro proteolytic degradation afforded by amide bond replacements extends to remote sites. | 4034413 |
| Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. | 3922013 |
| Unglycosylated rat alpha 1-proteinase inhibitor has a six-fold shorter plasma half-life than the mature glycoprotein. | 3871610 |
| Distribution and metabolism of dermorphin in rats. | 6522442 |
| Serum concentration patterns of an LHRH agonist, gonadotrophins and sex steroids after subcutaneous, vaginal, rectal and nasal administration of the agonist to pregnant rats. | 6433008 |
| Depressor and natriuretic activities of several atrial peptides. | 6239307 |
| The hydra head activator in human blood circulation. Degradation of the synthetic peptide by plasma angiotensin-converting enzyme. | 6086405 |
| Gastrin-releasing peptide: pharmacokinetics and effects on gastro-entero-pancreatic hormones and gastric secretion in normal men. | 6736205 |
| Corticotropin-releasing factor: pharmacokinetics in man. | 6605972 |
| Endocrine responses to exogenous bombesin and gastrin releasing peptide in conscious calves. | 6361234 |
| Disposition of human fibrinopeptide A in normal and nephrectomized rabbits. | 6658706 |
| In vitro synthesis of the tryptophan operon leader peptides of Escherichia coli, Serratia marcescens, and Salmonella typhimurium. | 6344071 |
| The in vivo metabolism of somatostatin 28: possible relationship between diminished metabolism and enhanced biological action. | 6127205 |
| Comparison of the gastric exocrine inhibitory activities and plasma kinetics of somatostatin-28 and somatostatin-14 in cats. | 6128770 |
| Degradation of cholecystokinin octapeptide, related fragments and analogs by human and rat plasma in vitro. | 6291099 |
| H-Pro-[3H]Leu-Gly-NH2: plasma profile and brain uptake following subcutaneous injection in the rat. | 6121002 |
| Radioimmunoassay study of hepatic clearance and disappearance half-time of somatostatin and vasoactive intestinal peptide in dogs. | 6117506 |
| The level and half-life of glutathione in human plasma. | 7439398 |
| Long term stability of lysine vasopressin and of specifically tritiated lysine vasopressin in weakly acidic aqueous solutions. | 7418787 |
| Anticandidal activity of 5-fluorocytosine-peptide conjugates. | 385880 |
| Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. | 730072 |
| Kinetics of human connecting peptide in normal and diabetic subjects. | 659633 |
| Capitalism, costs, and the shape of service: reply to a critique. | 641324 |
| Immunological half-life of porcine proinsulin C-peptide. | 1213660 |
| The distribution, half-life, and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in rats. | 4572061 |
| Lysistrata looks at another burden on health visitors. | 5092290 |
| Structure-activity relationships of synthetic adrenocorticotropic octadecapeptides with special reference to biological half-life. | 4327730 |